BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, Kinoshita Y. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther. 2000;14:1049-1056. [PMID: 10930899 DOI: 10.1046/j.1365-2036.2000.00799.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Tokoro C, Inamori M, Koide T, Sekino Y, Iida H, Sakamoto Y, Endo H, Hosono K, Takahashi H, Yoneda M, Yasuzaki H, Ogawa M, Abe Y, Kubota K, Saito S, Kawana I, Nakajima A, Maeda S, Matsuda R, Takahashi D. Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication. Med Sci Monit. 2011;17:CR235-CR240. [PMID: 21525804 DOI: 10.12659/msm.881762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Adachi K, Hashimoto T, Komazawa Y, Mihara T, Furuta K, Fujishiro H, Ishihara S, Amano Y, Hattori S, Kinoshita Y. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. Dig Liver Dis 2005;37:485-90. [PMID: 15975534 DOI: 10.1016/j.dld.2004.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kinoshita Y, Ishihara S. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia. Therap Adv Gastroenterol 2008;1:191-9. [PMID: 21180528 DOI: 10.1177/1756283X08098181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Adachi K, Komazawa Y, Mihara T, Fujishiro H, Ishihara S, Amano Y, Kinoshita Y. Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. J Clin Gastroenterol 2004;38:297-8. [PMID: 15128081 DOI: 10.1097/00004836-200403000-00020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
5 Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J Gastroenterol 2003; 9(11): 2583-2586 [PMID: 14606102 DOI: 10.3748/wjg.v9.i11.2583] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
6 Katz PO, Zavala S. Proton pump inhibitors in the management of GERD. J Gastrointest Surg. 2010;14 Suppl 1:S62-S66. [PMID: 19774429 DOI: 10.1007/s11605-009-1015-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
7 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
8 Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19:42. [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
9 Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, Ishizaki T. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther. 2002;16:837-846. [PMID: 11929404 DOI: 10.1046/j.1365-2036.2002.01229.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 2.1] [Reference Citation Analysis]
10 Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668-685. [PMID: 17335450 DOI: 10.1111/j.1572-0241.2006.00936.x] [Cited by in Crossref: 259] [Cited by in F6Publishing: 194] [Article Influence: 17.3] [Reference Citation Analysis]
11 Katz PO. Lessons Learned From Intragastric pH Monitoring: . Journal of Clinical Gastroenterology 2001;33:107-13. [DOI: 10.1097/00004836-200108000-00003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
12 Adachi K, Komazawa Y, Mihara T, Azumi T, Fujisawa T, Katsube T, Furuta K, Kinoshita Y. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine. J Gastroenterol Hepatol. 2005;20:1012-1015. [PMID: 15955208 DOI: 10.1111/j.1440-1746.2005.03917.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
13 Williams MP, Usselmann B, Chilton A, Sercombe J, Nwokolo CU, Pounder RE. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther. 2003;17:775-783. [PMID: 12641499 DOI: 10.1046/j.1365-2036.2003.01488.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
14 Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol. 2014;70:1073-1078. [PMID: 24996380 DOI: 10.1007/s00228-014-1713-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
15 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2514-2517 [DOI: 10.11569/wcjd.v12.i10.2514] [Reference Citation Analysis]
16 Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004;19:1105-10. [PMID: 15142200 DOI: 10.1111/j.1365-2036.2004.01949.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
17 Pan T, Wang YP, Liu FC, Yang JL. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough: a Cochrane systematic review. Chin J Dig Dis 2006;7:141-8. [PMID: 16808794 DOI: 10.1111/j.1443-9573.2006.00259.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Galmiche JP, Bruley Des Varannes S, Ducrotté P, Sacher-Huvelin S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004;19:655-62. [PMID: 15023167 DOI: 10.1111/j.1365-2036.2004.01893.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
19 Wang ZB, Chen LL, You XD. Efficacy of esomeprazole combined with hydrotalcite and mosapride in treatment of refractory gastroesophageal reflux disease. Shijie Huaren Xiaohua Zazhi 2007; 15(8): 901-904 [DOI: 10.11569/wcjd.v15.i8.901] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, Rumi MA, Watanabe M, Kinoshita Y. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001;16:1191-6. [PMID: 11903734 DOI: 10.1046/j.1440-1746.2001.02617.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 82] [Article Influence: 4.8] [Reference Citation Analysis]
21 Pfefferkorn MD, Croffie JM, Gupta SK, Molleston JP, Eckert GJ, Corkins MR, Fitzgerald JF. Nocturnal Acid Breakthrough in Children with Reflux Esophagitis Taking Proton Pump Inhibitors. Journal of Pediatric Gastroenterology & Nutrition 2006;42:160-5. [DOI: 10.1097/01.mpg.0000189354.48043.4e] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ono S, Kato M, Ono Y, Asaka M. New method for long-term monitoring of intragastric pH. World J Gastroenterol 2007; 13(47): 6410-6413 [PMID: 18081231 DOI: 10.3748/wjg.v13.i47.6410] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
23 Lou HY, Chang CC, Sheu MT, Chen YC, Ho HO. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol. 2009;65:55-64. [PMID: 18751689 DOI: 10.1007/s00228-008-0552-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
24 Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother. 2007;8:2701-2717. [PMID: 17956193 DOI: 10.1517/14656566.8.16.2701] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
25 Shimatani T, Inoue M, Kuroiwa T, Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther. 2004;19:113-122. [PMID: 14687173 DOI: 10.1046/j.1365-2036.2003.01821.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
26 Mart??nek J, Pantofl????kov?? D, Hucl T, Bene?? M, Dorta G, Luk???? M, ??pi????k J. Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole: . European Journal of Gastroenterology & Hepatology 2004;16:445-50. [DOI: 10.1097/00042737-200405000-00002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
27 Katz PO, Dudnick RS. Nocturnal acid breakthrough on proton pump inhibitor therapy: To treat or not to treat. Curr Treat Options Gastro 2008;11:29-34. [DOI: 10.1007/s11938-008-0004-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. J Gastroenterol Hepatol 2005;20:1886-91. [PMID: 16336449 DOI: 10.1111/j.1440-1746.2005.03896.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. European Journal of Gastroenterology & Hepatology 2004;16:441-3. [DOI: 10.1097/00042737-200405000-00001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
30 Sugimoto M, Jang JS, Yoshizawa Y, Osawa S, Sugimoto K, Sato Y, Furuta T. Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review. Diagn Ther Endosc. 2012;2012:791873. [PMID: 22851882 DOI: 10.1155/2012/791873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
31 Shimatani T, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment Pharmacol Ther 2003;18:1149-57. [PMID: 14653835 DOI: 10.1046/j.1365-2036.2003.01804.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
32 Katz PO, Tutuian R. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2001;15:371-384. [PMID: 11403533 DOI: 10.1053/bega.2001.0185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
33 Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632. [PMID: 11874994 DOI: 10.1053/gast.2002.31876] [Cited by in Crossref: 227] [Cited by in F6Publishing: 171] [Article Influence: 11.4] [Reference Citation Analysis]
34 Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Miyajima H. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012;36:627-634. [PMID: 22882464 DOI: 10.1111/apt.12014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
35 Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009;CD004275. [PMID: 19821323 DOI: 10.1002/14651858.cd004275.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
36 Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T. Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol 2018;74:45-52. [PMID: 28986609 DOI: 10.1007/s00228-017-2324-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
37 Fujiwara Y, Arakawa T, Fass R. Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol. 2012;47:760-769. [PMID: 22592763 DOI: 10.1007/s00535-012-0601-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
38 Shim YK, Kim N. The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. Korean J Gastroenterol 2017;70:4-12. [PMID: 28728310 DOI: 10.4166/kjg.2017.70.1.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
39 Furuta K, Adachi K, Komazawa Y, Mihara T, Miki M, Azumi T, Fujisawa T, Katsube T, Kinoshita Y. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2006;21:1581-1585. [PMID: 16928220 DOI: 10.1111/j.1440-1746.2006.04323.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
40 Ang TL, Fock KM. Nocturnal acid breakthrough: Clinical significance and management. J Gastroenterol Hepatol 2006;21:S125-8. [DOI: 10.1111/j.1440-1746.2006.04717.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
41 Furuta K, Kohata Y, Fujiwara Y, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Furuta T, Nio K, Iwakiri R, Inamori M, Kawamura O, Kusano M, Kato M, Kawami N, Iwakiri K, Takeuchi T, Higuchi K, Aimi M, Naora K, Fujimoto K, Arakawa T, Kinoshita Y. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr 2014;55:178-83. [PMID: 25411523 DOI: 10.3164/jcbn.14-41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Kirchhoff P, Wagner CA, Gaetzschmann F, Radebold K, Geibel JP. Demonstration of a functional apical sodium hydrogen exchanger in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2003;285:G1242-8. [PMID: 12907430 DOI: 10.1152/ajpgi.00165.2003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
43 Pan T, Wang Y, Guo Z, Wang Q. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev 2004;:CD004275. [PMID: 15495095 DOI: 10.1002/14651858.CD004275.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study. Aliment Pharmacol Ther 2006;24:1445-51. [PMID: 17032285 DOI: 10.1111/j.1365-2036.2006.03140.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
45 Adachi K, Furuta K, Miwa H, Oshima T, Miki M, Komazawa Y, Iwakiri K, Furuta T, Koike T, Shimatani T. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Dig Dis Sci. 2012;57:1609-1617. [PMID: 22367114 DOI: 10.1007/s10620-012-2087-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
46 Hamamoto N, Hashimoto T, Adachi K, Hirakawa K, Ishihara S, Inoue H, Taniura H, Niigaki M, Sato S, Kushiyama Y, Suetsugu H, Miyake T, Kinoshita Y. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. J Gastroenterol Hepatol 2005;20:281-6. [PMID: 15683433 DOI: 10.1111/j.1440-1746.2004.03546.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]